NCT01192165 - Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

September 14, 2010

Primary Completion Date

October 7, 2013

Study Completion Date

October 7, 2013

Conditions

Cancer

Interventions

DRUG

Trametinib (GSK1120212)

Investigational small molecule targeted therapy (MEK1/2 inhibitor)

DRUG

Docetaxel

Chemotherapy

DRUG

Erlotinib

Small molecule targeted therapy (EGFR inhibitor)

DRUG

Pemetrexed

Chemotherapy

DRUG

Carboplatin

Chemotherapy

DRUG

nab-Paclitaxel

Chemotherapy

DRUG

Cisplatin

Chemotherapy

Trial Locations (20)

12206

GSK Investigational Site, Albany

13385

GSK Investigational Site, Marseille

14033

GSK Investigational Site, Caen

23502

GSK Investigational Site, Norfolk

29605

GSK Investigational Site, Greenville

31052

GSK Investigational Site, Toulouse

37203

GSK Investigational Site, Nashville

44805

GSK Investigational Site, Saint-Herblain

75246

GSK Investigational Site, Dallas

75702

GSK Investigational Site, Tyler

77030

GSK Investigational Site, Houston

80218

GSK Investigational Site, Denver

85259

GSK Investigational Site, Scottsdale

89169

GSK Investigational Site, Las Vegas

91010

GSK Investigational Site, Duarte

95817

GSK Investigational Site, Sacramento

98684

GSK Investigational Site, Vancouver

M5G 2M9

GSK Investigational Site, Toronto

120-752

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul